SGLT2 Inhibitors May Reduce Blood Pressure in Type 2 Diabetes
Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.
Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.
Liraglutide and metformin yielded higher reductions in HbA1c levels when compared with gliclazide.
Updates to the US Preventive Services Task Force’s recommendations on obesity screening in children and adolescents focus on intensive behavioral interventions.
Semaglutide significantly increased insulin response and was well-tolerated in patients with type 2 diabetes.
There were no significant differences in hemoglobin A1c across the 3 self-monitoring blood glucose groups.
More patients in the device-supported group achieved a fasting self-monitored plasma glucose target of 90 to 130 mg/dL at week 16 without severe hypoglycemia.
HbA1c fell from 7.9%±2.0% at admission to 7.1%±1.5% at 3 months after discharge.
At 3 months, ezetimibe produced greater reductions in LDL cholesterol, whereas colesevelam produced greater reductions in HbA1c levels.
At 12 years of testosterone treatment, HbA1c decreased to 5.5±0.3%.
Researchers assessed whether neurolysis could alleviate pain associated with diabetic neuropathy.